Great Point Partners LLC Cyma Bay Therapeutics, Inc. Transaction History

Great Point Partners LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $6.13 Million - $10 Million	-1,042,500 Reduced 67.26%	507,500 $4.43 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $2.42 Million - $4.71 Million	750,561 Added 93.89%	1,550,000 $9.72 Million
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $2.21 Million - $3.4 Million	799,439 New	799,439 $2.8 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $6.04 Million - $13.6 Million	-998,841 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$8.16 - $13.42 $3.42 Million - $5.63 Million	-419,648 Reduced 29.58%	998,841 $13.3 Million
Q4 2018 Feb 15, 2019	BUY	$6.54 - $11.74 $9.28 Million - $16.7 Million	1,418,489 New	1,418,489 $11.2 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.